Skip to content
WealthTicker

Compare

NAVs as of 20 Aug 2026

ICICI Prudential Balanced Advantage FundRegular · IDCW1 of 4 funds

Add a second fund to compare. Until then every figure below is shown against the Dynamic Asset Allocation or Balanced Advantage median (38 funds), which is the only comparison one fund can support.

Growth of ₹100 (rebased over the selected window)

Common period 12 Jun 201420 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 50 history starts 18 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.

View as table
Growth of ₹100, sampled across the common period
DateICICI Prudential Balanced Advantage Fund
12 Jun 2014₹100.00
18 Jun 2015₹106.76
23 Jun 2016₹106.05
29 Jun 2017₹112.57
05 Jul 2018₹111.78
11 Jul 2019₹112.02
16 Jul 2020₹107.78
22 Jul 2021₹131.03
28 Jul 2022₹135.27
03 Aug 2023₹144.54
08 Aug 2024₹168.81
14 Aug 2025₹173.21
20 Aug 2026₹181.46
ICICI Prudential Balanced Advantage Fund compared on return, risk, benchmark-relative, cost and portfolio metrics, against the Dynamic Asset Allocation or Balanced Advantage median.
Metric
ICICI Prudential · Regular · IDCW
NAV ₹23.10
High risk
★★★★☆
Category median
Dynamic Asset Allocation or Balanced Advantage · 38 funds
+3.26%-1.74%
+7.96%+4.21%
+6.59%+2.98%
+5.16%+2.80%
+5.01%+3.99%
+6.75%
+5.11%+5.11%
+5.01%+4.14%
+5.06%+3.50%
Risk
7.04%9.32%
0.21-0.26
0.29-0.30
-27.83%-20.29%
Nifty 50
+0.21%-3.31%
0.530.63
61.3%56.3%
42.4%61.8%
1.54%2.38%
₹70,787Cr₹2,137Cr
Up to 1.00%
None
₹100
₹500
451%209%
Manish Banthia
12 Jun 2014
102
28.4%
10.3%

Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.